多発性硬化症市場：治療モダリティ別、用途別-2025-2030年の世界予測

多発性硬化症市場は、2023年に166億9,000万米ドルと評価され、2024年には180億5,000万米ドルに達すると予測され、CAGR 8.25％で成長し、2030年には290億9,000万米ドルに達すると予測されています。

多発性硬化症（MS）は、中枢神経系に影響を及ぼす慢性の自己免疫疾患であり、しびれなどの軽度のものから、麻痺や視力喪失などの重度のものまで、さまざまな症状を特徴とします。MSの市場範囲には、症状を管理し病気の進行を修正することを目的とした医薬品、診断薬、支持療法技術が含まれます。MS治療の必要性は、患者のQOL（生活の質）を向上させ、疾患の進行を遅らせることにあり、世界中のヘルスケアシステムに不可欠なものとなっています。治療には、インターフェロンのような疾患修飾療法、対症療法、高度画像診断が含まれ、最終用途は主に病院、診療所、在宅医療に及んでいます。市場成長は、診断率の上昇、治療における技術的進歩、高齢者人口の増加の影響を大きく受けています。同市場における最新のビジネスチャンスは、個別化医療、遺伝子治療、新規モノクローナル抗体を中心に展開されています。こうした機会を捉えるためには、研究開発への投資やバイオテクノロジー企業との戦略的提携が推奨されます。しかし、高額な治療費、複雑な医薬品承認プロセス、発展途上地域における認知度の低さといった課題が成長の妨げとなっています。さらに、市場参入企業はジェネリック医薬品やバイオシミラーとの競争に直面し、利益率を圧迫しています。技術革新の機が熟している分野には、早期診断のためのバイオマーカー開発、AIを活用した患者管理システム、費用対効果の高い医薬品製造プロセスなどがあり、新たな事業成長の道を提供しています。市場の成長ポテンシャルは高いもの、その性質上、規制当局の監視が厳しく、治療開発における倫理的配慮が必要です。こうした課題を克服するため、企業は世界な戦略的拡大に注力し、調査機関との連携を強化し、患者中心のアプローチを優先して製品を提供すべきです。また、教育やアドボカシー活動を重視することで、企業は市場参入の幅を広げ、競合情勢の中でMS治療の持続的成長を確保することができます。

市場力学：急速に進化する多発性硬化症市場の主要市場インサイトを公開

多発性硬化症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の研究開発活動への旺盛な投資
  • 人々の認識を高めるための政府の支援
  • 若年層および高齢層におけるMS発症率の上昇
• 市場抑制要因
  • 薬価が比較的高い
• 市場機会
  • コパキソンやタイサブリなどの経口薬への嗜好の高まり
  • 主要企業による新薬パイプラインの登場
• 市場の課題
  • 医薬品承認のための厳しい規制政策

ポーターの5つの力：多発性硬化症市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：多発性硬化症市場における外部からの影響の把握

外部マクロ環境要因は、多発性硬化症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析多発性硬化症市場における競合情勢の把握

多発性硬化症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス多発性硬化症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、多発性硬化症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨多発性硬化症市場における成功への道筋を描く

多発性硬化症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界の研究開発活動への積極的な投資
    • 国民の意識を高めるための政府の好意的な支援
    • 若者と高齢者のMS発症率の上昇
  • 抑制要因
    • 薬のコストが比較的高い
  • 機会
    • コパキソンやタイサブリなどの経口薬の好まれ方が増えている
    • 主要な市場プレーヤーによる新たな医薬品パイプラインの出現
  • 課題
    • 医薬品の承認に関する厳格な規制政策
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 多発性硬化症市場治療法別

• 注射剤
• 経口剤

第7章 多発性硬化症市場：用途別

• 病院
• 調査

第8章 南北アメリカの多発性硬化症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の多発性硬化症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの多発性硬化症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Synthetic Biologics, Inc.
• Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

• FIGURE 1. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLE SCLEROSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MULTIPLE SCLEROSIS MARKET DYNAMICS
• TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 21. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 33. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 35. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 70. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 78. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 80. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 100. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023

The Multiple Sclerosis Market was valued at USD 16.69 billion in 2023, expected to reach USD 18.05 billion in 2024, and is projected to grow at a CAGR of 8.25%, to USD 29.09 billion by 2030.

Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, characterized by symptoms ranging from mild, such as numbness, to severe, such as paralysis or loss of vision. The market scope for MS involves pharmaceuticals, diagnostics, and supportive care technologies aimed at managing symptoms and modifying disease progression. The necessity of MS treatments lies in improving patient quality of life and slowing disease progression, making them indispensable in healthcare systems worldwide. Applications include disease-modifying therapies like interferons, symptomatic treatments, and advanced imaging diagnostics, with primary end-use spanning hospitals, clinics, and home care settings. Market growth is heavily influenced by increased diagnosis rates, technological advancements in treatment, and a growing elderly population. The latest opportunities in the market revolve around personalized medicine, gene therapies, and novel monoclonal antibodies. To seize these opportunities, investment in R&D and strategic partnerships with biotech firms are recommended. However, challenges such as high treatment costs, complex drug approval processes, and limited awareness in developing regions hinder growth. Moreover, market players face competition from generic drugs and biosimilars, compressing profit margins. Areas ripe for innovation include biomarker development for early diagnosis, AI-driven patient management systems, and cost-effective drug manufacturing processes, offering new business growth avenues. Despite the robust growth potential, the market's nature is characterized by high regulatory scrutiny and ethical considerations in treatment developments. To navigate these challenges, firms should focus on global strategic expansion, enhance collaboration with research institutions, and prioritize patient-centric approaches in their product offerings. By emphasizing education and advocacy, companies can also broaden market reach and ensure sustained growth in the competitive landscape of MS treatments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiple Sclerosis Market

The Multiple Sclerosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Robust investment in research and development activities globally
  • Favorable government support to increase the awareness among people
  • Rising incidence of MS in young and elderly people
• Market Restraints
  • Relatively high cost of the drugs
• Market Opportunities
  • Increasing preference for oral drugs such as Copaxone and Tysabri
  • Emerging novel pipeline of drugs by key market players
• Market Challenges
  • Stringent regulatory policies for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Multiple Sclerosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiple Sclerosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiple Sclerosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiple Sclerosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiple Sclerosis Market

A detailed market share analysis in the Multiple Sclerosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiple Sclerosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiple Sclerosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiple Sclerosis Market

A strategic analysis of the Multiple Sclerosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiple Sclerosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan PLC, AstraZeneca PLC, Bayer AG, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Synthetic Biologics, Inc., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Sclerosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Modality, market is studied across Injectable Agents and Oral Agents.
• Based on Application, market is studied across Hospital and Research.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Robust investment in research and development activities globally
    • 5.1.1.2. Favorable government support to increase the awareness among people
    • 5.1.1.3. Rising incidence of MS in young and elderly people
  • 5.1.2. Restraints
    • 5.1.2.1. Relatively high cost of the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing preference for oral drugs such as Copaxone and Tysabri
    • 5.1.3.2. Emerging novel pipeline of drugs by key market players
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory policies for drug approval
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Multiple Sclerosis Market, by Treatment Modality

• 6.1. Introduction
• 6.2. Injectable Agents
• 6.3. Oral Agents

7. Multiple Sclerosis Market, by Application

• 7.1. Introduction
• 7.2. Hospital
• 7.3. Research

8. Americas Multiple Sclerosis Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Multiple Sclerosis Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Sclerosis Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan PLC
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Biogen Inc.
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche AG
• 8. GlaxoSmithKline PLC
• 9. Merck & Co. Inc.
• 10. Mylan N.V.
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. Sanofi S.A.
• 14. Synthetic Biologics, Inc.
• 15. Teva Pharmaceuticals Industries Ltd.